This is a timeline de-risking event, not a data readout. The next major catalyst is wet AMD Phase 3 topline data starting August 2026, followed by DME data in Q4 2027. Monitor for any safety signals or interim updates from the wet AMD program, which could inform DME expectations.
Price Chart
Executive Summary
EyePoint announced it has completed enrollment in both pivotal Phase 3 trials (COMO and CAPRI) of DURAVYU for diabetic macular edema, enrolling over 480 patients in five months. Topline 56-week data is expected in Q4 2027. This de-risks the DME program timeline but does not provide efficacy or safety results.
Key Facts
- Enrollment completed in both COMO and CAPRI Phase 3 DME trials of DURAVYU (vorolanib intravitreal insert)
- Over 480 patients enrolled across both trials in five months, ahead of schedule
- Topline 56-week data anticipated in Q4 2027
- DSMC reviewed safety data in May 2026 and recommended continuation of both wet AMD and DME programs as planned
- Phase 3 wet AMD program (LUGANO and LUCIA) topline data expected beginning August 2026
Financial Impact
No financial figures provided in the filing
Risk Factors
- Phase 3 non-inferiority trials may fail to meet primary endpoint
- Safety signals could emerge in larger Phase 3 population
- Competitive landscape includes existing anti-VEGF therapies and other sustained-delivery candidates
- FDA warning letter on Watertown manufacturing facility noted in risk factors
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-324866 |
| Document: eypt-ex99_1.htm | 0001193125-26-324866 |
| Document: 0001193125-26-324866-index-headers.html | 0001193125-26-324866 |
| Document: 0001193125-26-324866-index.html | 0001193125-26-324866 |
| Document: 0001193125-26-324866.txt | 0001193125-26-324866 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | 8-K | $0.4400 $0.3657 | ▲ +16.89% | ▲ +16.74% | $0.3724 (+15.36%) |
Oct 19, 2026 8d ago | 8-K | $0.4400 $0.3707 | ▲ +15.75% | ▲ +15.61% | $0.3724 (+15.36%) |
Oct 19, 2026 8d ago | Press Release | $0.4400 $0.3657 | ▲ +16.89% | ▲ +16.74% | $0.3724 (+15.36%) |
Oct 7, 2026 20d ago | SC 13G/A | $3.32 $3.01 | ▼ −9.34% | ▼ −8.36% | $0.3724 (−88.78%) |
Sep 10, 2026 6w ago | 8-K | $4.25 $3.99 | ▼ −6.12% | ▼ −5.62% | $0.3724 (−91.24%) |
Aug 18, 2026 9w ago | Insider Buy | $6.30 $4.99 | ▼ −20.79% | ▼ −20.41% | $0.3724 (−94.09%) |
Aug 17, 2026 10w ago | 8-K | $4.87 $4.87 | · 0.00% | ▲ +1.19% | $0.3724 (−92.35%) |
Aug 5, 2026 11w ago | 8-K | $12.25 $13.53 | ▲ +10.45% | ▲ +10.10% | $0.3724 (−96.96%) |
Jul 30, 2026 12w ago | 8-K | $12.86 $12.83 | ▼ −0.23% | ▼ −3.86% | $0.3724 (−97.10%) |
Jun 22, 2026 18w ago | 8-K | $13.73 $14.11 | ▲ +2.77% | ▲ +3.22% | $0.3724 (−97.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers